Andere Sprachen AEON Biopharma, Inc.

Aktien

A3EFKE

US00791X1000

AEON

Markt geschlossen - Nyse Andere Börsenplätze 22:00:00 17.05.2024			% 5 Tage	% 1. Jan.
1,53 ^USD	+2,00 %		-11,56 %	-78,75 %

09.05.	AEON Biopharma, Inc. gibt Update zur Entwicklungspipeline	CI
03.05.	US-Aktienmärkte schließen am Freitag nach schwachem Arbeitsmarktbericht höher	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AEON Biopharma, Inc. Provides Update on Development Pipeline	09.05.
US Equity Markets Close Higher Friday Following Weak Jobs Report	03.05.
Sector Update: Health Care Stocks Mixed Late Afternoon	03.05.
Sector Update: Health Care	03.05.
Top Midday Decliners	03.05.
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	03.05.
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial	03.05.
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine	03.05.
AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	12.04.
Sector Update: Health Care Stocks Slide Late Afternoon	01.04.
Sector Update: Health Care	01.04.
AEON Biopharma Shares Tumble on Wider Q4 Loss	01.04.
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
AEON Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.03.
AEON Biopharma, Inc. Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	19.03.
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	19.03.
Sector Update: Health Care Stocks Mixed Premarket Friday	19.01.
AEON Biopharma Says Cervical Dystonia Treatment Well-Tolerated in Phase 2 Study	19.01.
AEON Biopharma, Inc. Presents Positive Clinical and Pre-Clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, At TOXINS 2024	18.01.
AEON Biopharma, Inc. Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	12.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen AEON Biopharma, Inc.

Aktien

A3EFKE

US00791X1000

AEON

Andere Sprachen

Filter